Core Viewpoint - Polyrizon Ltd. has filed a divisional patent application for its Trap & Target (T&T) platform technology, aimed at enhancing intranasal drug delivery and improving medication effectiveness [1][2]. Company Overview - Polyrizon is a development-stage biotech company focused on innovative intranasal hydrogels, specifically designed for drug delivery through nasal sprays [6][7]. Patent Application Details - The divisional patent application is intended to protect the advanced intranasal drug delivery system, which increases the residence time of medications and ensures close contact with mucosal tissues [1][2]. - This application aligns with a recently announced U.S. patent application covering Polyrizon's two core technologies: Capture and Contain (C&C™) and Trap and Target (T&T) [1][5]. Trap & Target (T&T) Platform Features - The T&T platform aims to improve the bioavailability of active pharmaceutical ingredients (APIs) and address challenges in local and systemic drug delivery [2]. - Key features of the T&T platform include: - Prolonged residence time for better absorption and efficacy [6]. - Improved bioavailability by bypassing first-pass metabolism [6]. - Controlled release of APIs for optimal therapeutic levels [6]. - Prevention of dripping to maximize efficacy and patient comfort [6]. - Use of biodegradable components for safety and environmental friendliness [6]. - Versatility to accommodate various drug types, including small molecules, proteins, peptides, and antibodies [6]. CEO Commentary - The CEO of Polyrizon emphasized that the patent filing is a significant step in strengthening the company's intellectual property portfolio and believes the T&T platform can transform intranasal drug delivery, enhancing the efficacy and safety of various medications [4].
Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform